Data investigation

The Weight Comparison Used 257 People

A 30,458-patient study reported surgery producing 28.3% weight loss against 10.3% on GLP-1s, at lower two-year cost. The cost half uses the whole cohort. The weight half uses 1.6% of one arm.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

A study of 30,458 patients reported that bariatric surgery produced 28.3% weight loss against 10.3% on GLP-1 medications, at lower two-year cost.[1] The cost half rests on the whole cohort and deserves to be taken seriously. The weight half rests on 257 of the 16,357 people in the drug arm, and that is a different kind of number.

What the study compared

Researchers linked an insurance claims database to a health system’s medical records and identified adults with class II or III obesity who had either metabolic bariatric surgery (sleeve gastrectomy or gastric bypass) or a GLP-1 prescription. Propensity score weighting balanced the groups on prior spending, health care use, age, sex, comorbidities and smoking. The result was 14,101 surgical patients and 16,357 on medication, followed for a little under three years on average.

What each finding was based on.[1]
FindingResultSample used
Total cost over 2 years$63,483 (GLP-1) vs $51,794 (surgery)The full cohort, 30,458
Total weight loss10.3% (GLP-1) vs 28.3% (surgery)257 and 1,291

Who those 257 people are

Weight appears in the analysis only for patients whose weights were recorded in that health system’s medical records: 1.6% of the drug arm and 9.2% of the surgical arm. Those are not random samples. A surgical patient has scheduled follow-up appointments where they are weighed as a matter of protocol. Someone filling a GLP-1 prescription may have no recorded weight in that system at all, and the ones who do are those with a particular pattern of engagement with that particular network.

Which direction that biases the result cannot be known from the outside, and that is the problem. The more than 98% of the drug arm whose weights are missing could be doing better than the 257 or worse. What can be said is that a comparison built on 1.6% of one arm and 9.2% of the other is not the comparison the propensity weighting was designed to protect, because the weighting balanced the full cohort and not these two fragments.

The careful matching was done on 30,458 people. The headline number was computed on 1,548 of them.

And the drug arm is not one drug

The GLP-1 group pooled dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide and tirzepatide. Those agents differ enormously in what they do to weight. The older ones, such as exenatide, were never marketed for weight loss and produce a fraction of the effect of the newest two.

So 10.3% is an average across a class whose members are not interchangeable, in a period during which prescribing shifted heavily toward the strongest agents. It is a fair description of “people who took some GLP-1 during these years.” It is not a fair description of what someone starting tirzepatide today should expect, and the figure will be quoted as though it were.

The cost finding is the solid half

Two-year costs came to $63,483 for the medication group against $51,794 for surgery, with the difference driven by pharmacy spending that stayed higher throughout the second year. That analysis used the entire cohort, the difference is large, and it makes an obvious point: an operation is paid for once, and a prescription is paid for every month for as long as it works.

Two years is also the most favorable window surgery could be given. Surgical costs and surgical risks are concentrated at the start, then largely stop. Drug costs keep accumulating. Extend the window and the gap widens; shorten it below the surgical episode and it reverses. The choice of window is doing real work in that comparison, and it is a defensible choice rather than a hidden one.

The authors conclude by asking whether surgery should still be treated as a last resort. That is a reasonable question and the cost data support raising it. What the cost data cannot address is the thing that makes surgery a last resort for most people: it is irreversible, it carries operative risk, and it changes how someone eats permanently. Those are not costs and do not appear in a claims database.

Among the authors’ declared interests are personal fees from Medtronic, a manufacturer of surgical devices, alongside Novo Nordisk and Eli Lilly. That is disclosed in the paper, it is unremarkable in this field, and it is context for a conclusion favoring surgery.

What to take from it

  • Surgery produces more weight loss than these drugs. That is established elsewhere by better evidence; we cover a cleaner head-to-head in surgery versus GLP-1 drugs. Nothing here is surprising, and this study’s particular weight numbers are weakly supported.
  • The ongoing cost difference is real and is the study’s useful contribution.
  • Do not carry the 10.3% anywhere. It averages six drugs of very different potency, measured in 1.6% of the people taking them.
  • The decision is not primarily arithmetic. Irreversibility, operative risk and permanent changes to eating are the substance of it.

Frequently Asked Questions

It produces more weight loss, which is well established. This study reported 28.3% against 10.3%, but that comparison used weight data from only 257 of 16,357 patients in the drug arm and 1,291 of 14,101 in the surgical arm.
Weight was available only for patients whose weights were recorded in one health system's records. Surgical patients are weighed at protocol follow-ups; medication patients often are not. The careful statistical matching was done on all 30,458 people, while the headline was computed on 1,548 of them.
No. That figure averages six different drugs, including older ones never marketed for weight loss that produce a fraction of the effect of semaglutide or tirzepatide.
Over the two years studied, yes. Surgery cost $51,794 against $63,483 for medication, because an operation is paid for once and a prescription is paid for continuously. That analysis used the full cohort and is the study's strongest finding.
The authors raise that question and the cost data support raising it. Cost is not what makes surgery a last resort, though. Irreversibility, operative risk and permanent changes to how someone eats are, and none of those appear in a claims database.

References

  1. 1.Barrett TS, Hafermann JO, Richards S, et al. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists JAMA Surgery. 2025. PMID: 40960852.

When Is It Safe to Have the Skin Removed?

Large weight loss leaves skin that does not retract. A review of 12 studies puts the weight plateau at 53 weeks, and the more consequential finding is about what happens if you stop the drug afterward.

6 min read

The Day the Balloon Comes Out

An intragastric balloon is removed on a scheduled date, which makes it an unusually clean experiment in what happens when a weight intervention ends. One group began regaining. The other kept losing.

6 min read

The Group That Lost Least Did Best

A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.

6 min read

Surgery Versus GLP-1 Drugs: Reading an Indirect Comparison

A network meta-analysis of 30 trials put surgery about 10 points ahead on total weight loss. Nobody was randomized to surgery versus a drug, and against tirzepatide alone the difference vanished.

6 min read

Fat-to-Muscle Ratio: Surgery Versus Drugs

The lean-to-fat ratio improved in both groups at 6, 12 and 24 months. Everyone loses lean tissue when losing weight. The question is the mix, and both interventions improved it.

5 min read

The Line Is Drawn by Surgery

A meta-regression found study arms with greater average weight loss had higher rates of fatty liver disease resolving. The authors say plainly it cannot establish cause, and a handful of surgical arms are pulling the line.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.1

Collective

Flat any-dose pricing, if you can absorb a $199 annual membership on top

From $59/mo + membership

Get started →
Read full review →
9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →